{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:22:05Z","timestamp":1791105725598,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2005,6,13]],"date-time":"2005-06-13T00:00:00Z","timestamp":1118620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa\u2010induced dyskinesias in Parkinson's disease (PD) in an open\u2010label pilot study. Nine PD patients who were experiencing peak\u2010dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent <jats:italic>on<\/jats:italic> without dyskinesia or with nontroublesome dyskinesia (good <jats:italic>on<\/jats:italic> time). The mean dose of LEV at endpoint was 625 \u00b1 277 mg\/day. LEV significantly improved percent of the awake day <jats:italic>on<\/jats:italic> without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% \u00b1 12% vs. 61% \u00b1 17%; <jats:italic>P<\/jats:italic> = 0.02). Percent <jats:italic>on<\/jats:italic> time with troublesome dyskinesia decreased from 23% \u00b1 10% at baseline to 11% \u00b1 6% at endpoint, although not significantly. There was no significant increase in <jats:italic>off<\/jats:italic> time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak\u2010dose dyskinesia for at least 25% of the awake day, LEV significantly improved <jats:italic>on<\/jats:italic> time without dyskinesia or with nontroublesome dyskinesia. \u00a9 2005 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.20563","type":"journal-article","created":{"date-parts":[[2005,6,13]],"date-time":"2005-06-13T19:16:37Z","timestamp":1118690197000},"page":"1205-1209","source":"Crossref","is-referenced-by-count":55,"title":["Open\u2010label pilot study of levetiracetam (Keppra) for the treatment of levodopa\u2010induced dyskinesias in Parkinson's disease"],"prefix":"10.1002","volume":"20","author":[{"given":"Theresa A.","family":"Zesiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William O.","family":"Tatum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,6,13]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/334345a0"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.34.6.668"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.suppl_1.S51"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.2.236"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10542"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.11.065"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.6.1112"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10118"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20233"},{"key":"e_1_2_5_11_2","series-title":"Recent developments in Parkinson's disease","first-page":"153","author":"Fahn S","year":"1987"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00003"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20248"},{"key":"e_1_2_5_14_2","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_5_15_2","first-page":"218","volume-title":"ECDEU assessment manual for psychopharmacology, revised","author":"Guy W","year":"1976"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540"},{"key":"e_1_2_5_17_2","volume-title":"Physicians' desk reference","year":"2004"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.8.1392"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.3.465"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130606"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.3.724"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.2.393"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007759"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)91004-7"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5.1323"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.066191"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.036558"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.20563","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.20563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:13:24Z","timestamp":1760951604000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.20563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,13]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1002\/mds.20563"],"URL":"https:\/\/doi.org\/10.1002\/mds.20563","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,13]]}}}